Trevena, Inc. (TRVN)
Stock Price:
$2.37 USD
-0.14 (-5.58%)
Updated December 1, 4:00 PM EST - Market closed
Pre-market: $2.35 -0.02 (-0.84%) Dec 2, 4:20 AM
Key Info
| Market Cap |
372.16M |
| Revenue (ttm) |
3.03M |
| Net Income (ttm) |
-23.94M |
| Shares Out |
157.03M |
| EPS (ttm) |
-0.22 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$2.37 |
| Previous Close |
$2.51 |
| Change ($) |
-0.14 |
| Change (%) |
-5.58% |
| Day's Open |
2.45 |
| Day's Range |
2.37 - 2.49 |
| Day's Volume |
3,477,569 |
| 52-Week Range |
0.48 - 3.26 |
More Stats
| Market Cap |
372.16M |
| Enterprise Value |
266.14M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
157.03M |
| Float |
n/a |
| EPS (basic) |
-0.23 |
| EPS (diluted) |
-0.22 |
| FCF / Share |
-0.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
23.66M |
| Short Ratio |
5.11 |
| Short % of Float |
n/a |
| Beta |
2.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
122.78 |
| PB Ratio |
3.30 |
| Revenue |
3.03M |
| Operating Income |
-23.94M |
| Net Income |
-23.94M |
| Free Cash Flow |
-21.07M |
| Net Cash |
106.02M |
| Net Cash / Share |
0.68 |
| Gross Margin |
1.02% |
| Operating Margin |
-789.87% |
| Profit Margin |
-789.90% |
| FCF Margin |
-695.05% |
| ROA |
-16.74% |
| ROE |
-32.85% |
| ROIC |
-155.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.25*
(121.52% upside)
Low
5.00
Current: $2.37
High
6.00
Target: 5.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.03 | 5.73 | - | 3.75 | 6.25 | - | 0.13 | 0.81 |
| Revenue Growth | -99.46% | - | - | -40% | - | - | -83.29% | - |
| Gross Profit | 0.03 | 5.73 | - | 3.75 | 6.25 | - | 0.13 | 0.81 |
| Operating Income | -26.58 | -30.50 | -70.39 | -102 | -50.62 | -49.95 | -23.35 | -15.61 |
| Net Income | -24.87 | -30.78 | -71.87 | -103 | -50.53 | -49.70 | -23.25 | -15.64 |
| Shares Outstanding | 91.68 | 73.56 | 59.44 | 52.40 | 43.79 | 24.66 | 0.79 | 0.67 |
| Earnings Per Share | -0.27 | -0.42 | -1.21 | -1.97 | -1.15 | -2.02 | -29.71 | -23.70 |
| Operating Cash Flow | -23.67 | -25.38 | -71.26 | -91.55 | -40.08 | -39.78 | -24.24 | -14.81 |
| Capital Expenditures | - | -0.17 | -3.50 | -0.61 | -0.38 | -0.44 | -0.14 | -0.02 |
| Free Cash Flow | -23.67 | -25.54 | -74.75 | -92.16 | -40.45 | -40.22 | -24.38 | -14.83 |
| Cash & Equivalents | 37.11 | 62.79 | 67.51 | 112 | 173 | 107 | 38.08 | 6.95 |
| Total Debt | 13.46 | 17.40 | 28.18 | 18.33 | 18.19 | 1.70 | - | 4.87 |
| Net Cash / Debt | 23.65 | 45.38 | 39.33 | 93.47 | 155 | 105 | 38.08 | 2.08 |
| Assets | 46.99 | 66.78 | 72.72 | 115 | 175 | 108 | 42.39 | 8.09 |
| Liabilities | 16.92 | 25.25 | 38.09 | 36.07 | 32.22 | 9.04 | 3.40 | 8.13 |
| Book Value | 30.08 | 41.53 | 34.63 | 78.58 | 143 | 99.20 | -81.57 | -59.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Trevena, Inc. |
| Country |
United States |
| Employees |
24 |
| CEO |
Carrie L. Bourdow |
Stock Information
| Ticker Symbol |
TRVN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TRVN |
| IPO Date |
January 31, 2014 |
Description
Trevena, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.